Insulet (PODD) EBITDA (2010 - 2026)

Insulet has reported EBITDA for 17 years, with the latest figure at $122.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 37.5% year-over-year to $122.1 million; the trailing twelve-month figure through Mar 2026 stood at $507.2 million (up 48.87% YoY), and the FY2025 full-year result was $473.8 million, up 53.38% from the prior year.
• EBITDA for Q1 2026 stood at $122.1 million, down from $146.3 million in the prior quarter.
• The five-year high for EBITDA was $146.3 million in Q4 2025, with the low at -$26.7 million in Q2 2022.
• Historically, EBITDA has averaged $68.4 million across 5 years, with a median of $56.9 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA slumped 201.52% — and 2023, when it jumped 1789.66%.
• Insulet's EBITDA stood at $23.5 million in 2022, then soared by 353.19% to $106.5 million in 2023, then rose by 2.63% to $109.3 million in 2024, then surged by 33.85% to $146.3 million in 2025, then slipped by 16.54% to $122.1 million in 2026.
• The last three EBITDA figures came in at $122.1 million (Q1 2026), $146.3 million (Q4 2025), and $117.7 million (Q3 2025), per Business Quant data.